After major sell-off over the past year, Brainstorm Cell Therapeutics (NASDAQ:BCLI) continues to trade lower. The stock has slumped almost 80% from its 52-week and just 15% away from its 52-week low of $2.92. Will the stock see a relief rally?
BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at ISCT 2021 New Orleans VIRTUAL Meeting
- BCLI announced the presentation today of a poster titled, “Molecular Mechanisms Underlying MSC-NTF (NurOwn®) Exosome Benefits in a Mouse LPS-induced ARDS Model” at the ISCT 2021 New Orleans VIRTUAL Meeting, being held from May 25-28, 2021. The poster will be presented during Virtual Poster Hall Session 2: May 25, 20:00-21:30 EDT.
- One of the most severe complications of the current COVID-19 pandemic is acute respiratory distress syndrome (ARDS). ARDS is caused by increased amounts of pro-inflammatory cytokines, leading to severe lung damage and loss of lung function.
- Results from a study in a mouse model of lipopolysaccharide (LPS)-induced ARDS showed that intratracheal administration of NurOwn (MSC-NTF cells)-derived exosomes resulted in a statistically significant improvement in multiple lung parameters and superior results compared to MSC exosomes. These included functional lung recovery, reduction in pro-inflammatory cytokines (IFN-γ, IL-6, RANTES, and TNF-α) and attenuation of lung damage (fibrin deposition) and coagulation biomarkers (tissue factor and thrombin–antithrombin complex).
- Analysis of the respective protein cargo demonstrated higher levels of key regulatory molecules in MSC-NTF exosomes compared to MSC exosomes that may attenuate lung inflammation and promote lung repair, including leukemia inhibitory factor (LIF); amphiregulin (AREG); hepatocyte growth factor (HGF); and tumor necrosis factor stimulated gene-6 (TSG-6). These positive preclinical results suggest that intratracheal-delivered may be suitable as a therapy for COVID-19 induced ARDS. The higher effectiveness of MSC-NTF exosomes on ARDS physiological, pathological, and biochemical parameters, compared to exosomes isolated from non-induced MSCs, may be related to their enhanced protein cargo.
On Tuesday, BCLI stock decreased 0.90% to end the session at $3.39. After opening at $3.40, the stock moved within a narrow range of $3.3550 – 3.4300. Yesterday’s volume was lower than the average volume with 318K shares traded for the session, compared to its average volume of 698K shares.